Key facts
- It has raised $2.4M across 1 recorded rounds; the latest was Seed Round ($2.4M) in Sep 2009.
- Notable investors include US National Science Foundation, gBETA, Innovate Alabama, Alabama Launchpad.
- iXpressGenes has filed 1 Form D with the SEC, most recently Jun 2025 ($2.4M sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for iXpressGenes
Funding rounds
1 roundsAbout iXpressGenes
Developer of a gene expression and protein engineering technology designed to detect trauma-induced conditions at the molecular level before symptoms appear. The company's technology offers advanced RNA analysis, specialized biomarkers for trauma and autoimmune response, and a blood test, enabling healthcare providers to intervene early, improving diagnosis and treatment of trauma-related diseases.
- Sector
- Healthcare
- HQ
- Huntsville, AL, United States
- Founded
- 2006
- Employees
- 7
- Website
- ixpressgenes.com/
- Ownership
- Privately Held (backing)
iXpressGenes doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iXpressGenes shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iXpressGenes in its N-PORT filings yet. We sweep new filings monthly.